PATENT CLAIM ANALYSIS

Application Number: 16026758
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "171000"]

Abstract:
A combination therapy for the treatment of cancers refractory to anti-androgen therapy; particularly prostate cancer. The combination therapy includes a pharmaceutically effective amount of enzalutamide, bicalutamide, and/or abiraterone combination with ranolazine, perhexiline, and/or etomoxir. The invention also includes methods for treating cancer. The method can include the steps of administering to the subject a pharmaceutically effective amount of an anti-androgen drug in combination with a pharmaceutically effective amount of a drug that block or reduces lipid metabolism. The cancer can be prostate cancer. In a beneficial embodiment the prostate cancer is unresponsive or has a reduced responsiveness to anti-androgen treatment. The pharmaceutically effective amount of an anti-androgen drug can enzalutamide and abiraterone. It can also be combinations, analogs and derivatives of enzalutamide and/or abiraterone. The pharmaceutically effective amount of a drug that blocks or reduces lipid metabolism can be ranolazine, perhexiline, or etomoxir. It can also be combinations, analogs and derivatives of ranolazine, perhexiline, and/or etomoxir.

Claim (Index 10):
A method of treating cancer in a subject comprising the steps of:\n administering a first drug to the subject wherein the first drug is enzalutamide, abiraterone, bicalutamide, galeterone, or AR-509; assessing the responsiveness of the cancer in the subject to the administration of the first drug; and administering a second drug to the subject responsive to the assessment that the cancer of the subject has limited or no response to the first drug wherein the second drug is ranolazine, perhexiline, or etomoxir.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 95.0
- Lexical Diversity: 2.72308
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14758938', '14792490', '14946067', '15923668', '15331777']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.738759094394637
- 35 USC 102 Novelty (BERT): 0.5376726972681622
- Combined Prediction Score: 0.7186504546819896
- Mean Citation Score: 369.43143
- Max Citation Score: 386.356
- Similarity Product: 256.9016701316833

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test